Premium
Androphilic protein studied histochemically in stage D2 prostatic cancer
Author(s) -
Yamaguchi Kunio,
Sumiya Hidenori,
Fuse Hideki,
Matsuzaki Osamu,
Ito Haruo,
Ki Jun Shimaza
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19880401)61:7<1425::aid-cncr2820610724>3.0.co;2-b
Subject(s) - dihydrotestosterone , fluorescence , cancer , androgen receptor , endocrine system , fluorescent staining , medicine , stage (stratigraphy) , androgen , endocrinology , hormone , progestin , staining , cancer research , pathology , prostate cancer , biology , paleontology , physics , quantum mechanics
Androphilic protein in prostatic cancer was histochemically observed with dihydrotestosterone (DHT), R 1881, and mibolerone as ligands. Cancer cells were equally stained with fluorescent R 1881 and mibolerone, and this fluorescence seems to be made up of both the androgen receptor and progestin‐binding protein. The staining with fluorescent DHT was weak. Sixty‐two Stage D2 prostatic cancer patients were examined with histochemical androphilic protein, and they then received endocrine therapy. The presence of fluorescence of R 1881 was not correlated with grade, but a relationship between the presence of fluorescence and the response to endocrine therapy was noticed 6 months after the start of treatment. Moreover, fluorescence‐positive patients showed better survival than fluorescence‐negative patients. An examination with fluorescent DHT revealed a similar tendency to that of R 1881, but the frequency of positive fluorescence was lower, indicating that R 1881 is a suitable ligand in this type of study.